| 1 |
31534549 | Prostaglandin E2 induces DNA hypermethylation in gastric cancer in vitro and in vivo. | 2019 |
1 |
| 2 |
29732985 | Treatment of Chronic Articular Pain in Adult People with Hemophilia. | 2018 |
1 |
| 3 |
29928230 | Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction. | 2018 |
1 |
| 4 |
30195234 | Computer-aided identification of natural lead compounds as cyclooxygenase-2 inhibitors using virtual screening and molecular dynamic simulation. | 2018 Dec |
1 |
| 5 |
26982261 | Deciphering the mechanism behind the varied binding activities of COXIBs through Molecular Dynamic Simulations, MM-PBSA binding energy calculations and per-residue energy decomposition studies. | 2017 Mar |
1 |
| 6 |
27388291 | Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx. | 2017 Jun |
1 |
| 7 |
28105626 | [Effect of polyunsaturated fatty acids ω-3 and ω-6 on angiogenesis formation in human gastric cancer]. | 2017 Jan 25 |
2 |
| 8 |
28375409 | Hot Topics in Primary Care: The Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs: Putting the Evidence in Perspective. | 2017 Apr |
2 |
| 9 |
27324742 | Rational Design and Synthesis of Biologically Active Disubstituted 2(3H) Furanones and Pyrrolone Derivatives as Potent and Safer Non Steroidal Anti-inflammatory Agents. | 2016 |
1 |
| 10 |
27537326 | Hepatotoxicity induced by coxibs: how concerned should we be? | 2016 Nov |
1 |
| 11 |
25806762 | [Cardiovascular safety of non-steroidal anti-inflammatory drugs]. | 2015 Mar 24 |
1 |
| 12 |
24365321 | Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. | 2014 |
2 |
| 13 |
25408841 | Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. | 2014 Nov 13 |
1 |
| 14 |
25559449 | Ultrahigh-performance liquid chromatography/tandem mass spectrometry method for evaluating enzyme activity and screening inhibitors of cyclooxygenase-2. | 2014 Aug 30 |
1 |
| 15 |
23031659 | Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity? | 2013 May-Jun |
1 |
| 16 |
23441769 | How safe is Celecoxib for Asian-Indian patients with rheumatic diseases? | 2013 Feb |
1 |
| 17 |
23454135 | Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes. | 2013 May 13 |
1 |
| 18 |
23580446 | Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. | 2013 Jul |
1 |
| 19 |
21507199 | IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2. | 2012 Mar |
1 |
| 20 |
22002318 | A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth. | 2012 Feb |
2 |
| 21 |
22819703 | Phospholipase A₂ activities in skin physiology and pathology. | 2012 Sep 15 |
1 |
| 22 |
21548865 | Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin. | 2011 |
2 |
| 23 |
21600026 | Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process. | 2011 May 21 |
1 |
| 24 |
21752640 | Bioactive sulfoximines: syntheses and properties of Vioxx analogs. | 2011 Aug 15 |
1 |
| 25 |
21830840 | Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety. | 2011 Sep 1 |
1 |
| 26 |
22114865 | An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect? | 2011 Nov 24 |
4 |
| 27 |
24250402 | Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. | 2011 Fall |
1 |
| 28 |
20166930 | Progress in COX-2 inhibitors: a journey so far. | 2010 |
1 |
| 29 |
20569079 | Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. | 2010 Nov |
1 |
| 30 |
20692174 | Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors. | 2010 Sep 1 |
3 |
| 31 |
21373319 | Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet. | 2010 Aug 20 |
1 |
| 32 |
24825998 | Rofecoxib prevents ctdsDNA against damage induced by copper sulfate and ultraviolet B radiation in vitro study. | 2010 Dec |
2 |
| 33 |
19374865 | PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells. | 2009 Mar 15 |
1 |
| 34 |
19530988 | Prostaglandin E(2) synthase inhibition as a therapeutic target. | 2009 Jul |
1 |
| 35 |
17963198 | Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. | 2008 Jan |
1 |
| 36 |
18163459 | Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. | 2008 Jul |
1 |
| 37 |
18507001 | Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. | 2008 Mar-Apr |
1 |
| 38 |
18541831 | Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. | 2008 Jun 9 |
1 |
| 39 |
18606461 | Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. | 2008 Aug |
1 |
| 40 |
18690976 | Risk-benefit perspectives in COX-2 blockade. | 2008 Jan |
2 |
| 41 |
18802217 | A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. | 2008 Aug |
1 |
| 42 |
19075637 | Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. | 2008 Dec |
2 |
| 43 |
20046772 | A Study on Improvement of Solubility of Rofecoxib and its effect on Permeation of Drug from Topical Formulations. | 2008 Jul-Aug |
1 |
| 44 |
16645868 | [Transient global amnesia (TGA) during an oral provocation test]. | 2007 Feb |
2 |
| 45 |
17222987 | A pathogenetic mechanism for COX-2 inhibitor-induced cardiovascular events proposed to be useful in structuring medical testimony in rofecoxib trials. | 2007 |
1 |
| 46 |
17305573 | Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. | 2007 |
1 |
| 47 |
17316360 | Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. | 2007 Mar-Apr |
1 |
| 48 |
17387473 | Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. | 2007 Oct |
1 |
| 49 |
17453399 | Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. | 2007 Feb |
2 |
| 50 |
17504133 | Dual carbonic anhydrase--cyclooxygenase-2 inhibitors. | 2007 |
2 |